Next 10 |
home / stock / nevpf / nevpf news
NeuroVive Pharmaceutical AB ( OTCQX:NEVPF ): Q4 GAAP EPS of -SEK0.15. More news on: NeuroVive Pharmaceutical AB, Neurovive Pharmaceutical AB ADR, Earnings news and commentary, Healthcare stocks news, , Read more ...
STOCKHOLM , Feb. 19, 2020 /PRNewswire/ -- Important events in 2019 KL1333 NeuroVive enrolls first subject in its European KL1333 phase Ia/b clinical study &...
NeuroVive Pharmaceutical AB ( OTCQX:NEVPF ) has fully and finally settled the dispute with CicloMulsion AG regarding certain pharmaceutical technology. The companies entered into a License Agreement in 2004. More news on: NeuroVive Pharmaceutical AB, Healthcare stocks news, Read...
LUND, Sweden , Dec. 16, 2019 /PRNewswire/ -- NeuroVive Pharmaceutical AB (Nasdaq Stockholm: NVP, OTCQX: NEVPF) announced today that it has fully and finally settled the dispute with CicloMulsion AG regarding certain pharmaceutical technology. In 2004, NeuroVive entered into a License A...
- Continued Progress in KL1333 STOCKHOLM , Nov. 20, 2019 /PRNewswire/ -- Important events July - September NeuroVive initiates second part of its ongoing KL1333 Phase Ia/b clinical study NeuroSTAT receives Fast Track designation from the US Food and Drug Administration. ...
Mitochondrial medicine probably isn’t the last thing your family talked about over dinner, but it may be the key to dealing with some very difficult medical conditions. NeuroVive Pharmaceutical AB (OTCQX: NEVPF) is a niche biotech company that is working on novel solutions to serious me...
NeuroVive Pharmaceutical AB ( OTCQX:NEVPF ): Q2 GAAP EPS of -SEK0.14. More news on: NeuroVive Pharmaceutical AB, Neurovive Pharmaceutical AB ADR, Earnings news and commentary, Healthcare stocks news, , Read more ...
Focus on genetic mitochondrial diseases STOCKHOLM , Aug. 21, 2019 /PRNewswire/ -- Important events April – June The US Food and Drug Administration, FDA, approves NeuroVive's IND (Investigational New Drug) application, enabling clinical studies in the US with the ...
LUND, Sweden , Aug. 20, 2019 /PRNewswire/ -- NeuroVive Pharmaceutical AB (Nasdaq Stockholm: NVP) (OTCQX: NEVPF) today announced that the company will host a Capital Markets Day in Stockholm on 9 October, 2019 , for investors, analysts and media. Presentations wil...
LUND, Sweden , July 27, 2019 /PRNewswire/ -- NeuroVive Pharmaceutical AB (Nasdaq Stockholm: NVP) (OTCQX: NEVPF) today announced that the company's candidate drug NeuroSTAT, in development for treatment of moderate to severe traumatic brain injury, TBI, has received Fast Tra...
News, Short Squeeze, Breakout and More Instantly...
Neurovive Pharm Ab Ord Company Name:
NEVPF Stock Symbol:
OTCMKTS Market:
STOCKHOLM , Feb. 19, 2020 /PRNewswire/ -- Important events in 2019 KL1333 NeuroVive enrolls first subject in its European KL1333 phase Ia/b clinical study &...
LUND, Sweden , Dec. 16, 2019 /PRNewswire/ -- NeuroVive Pharmaceutical AB (Nasdaq Stockholm: NVP, OTCQX: NEVPF) announced today that it has fully and finally settled the dispute with CicloMulsion AG regarding certain pharmaceutical technology. In 2004, NeuroVive entered into a License A...
- Continued Progress in KL1333 STOCKHOLM , Nov. 20, 2019 /PRNewswire/ -- Important events July - September NeuroVive initiates second part of its ongoing KL1333 Phase Ia/b clinical study NeuroSTAT receives Fast Track designation from the US Food and Drug Administration. ...